Two Novel Diabetes Management Systems Aim to Ease Care

Miriam E Tucker


December 09, 2016

Two new novel diabetes management platforms, the direct-to-consumer One Drop Premium and the prescription-only Insulia Diabetes Management Companion, have been newly licensed in both the United States and Europe.

Both technologies received both US Food and Drug Administration (FDA) 510(k) clearance and CE mark approval on December 6, 2016.

One Drop Aims for Patient Buy-In: Unlimited Supplies and Support

The "One Drop Premium" is a monthly subscription service that features a sleek blood glucose monitor along with at-home delivery of unlimited test strips and other testing supplies. It also includes Apple iOS, Apple Watch, and Android diabetes management apps that include in-app 24/7 on-demand access to a personal certified diabetes educator (CDE).

The apps "allow you to log in and analyze glucose, food, meds, and activity all in one place, set daily diabetes management goals, track daily progress, and interact with a worldwide community of people living with diabetes," One Drop spokesperson Rachel Sanchez told Medscape Medical News.

Currently, the One Drop is fully integrated with the Apple iOS and Watch apps, allowing for users to sync data from other health apps, including continuous glucose monitors (CGMs), Bluetooth meters, and other food and activity trackers. The integration also allows users to share their data with their healthcare providers.

"We look forward to bringing the same integrated experience to Android very soon," Ms Sanchez said.

One Drop is not currently covered by any US insurance plans, but the total out-of-pocket cost, around $33 to $40 a month depending on subscription plan, is less than many monthly copays, she stressed.

Asked to comment, David T Ahn, MD, an endocrinologist and diabetes technology expert at the University of California, Los Angeles, told Medscape Medical News that One Drop's approach "refreshingly focuses on getting buy-in from patients: design aesthetics, unlimited test strips, and an emphasis on social networking. I'm excited for any solution that aims to build enthusiasm for testing blood sugar."

However, he cautioned, "I am wary of how the in-app 'expert' interaction with CDEs will play out, because there is a very fine line between casual behavioral guidance and medical/clinical advice."

One Drop chief executive officer and founder Jeff Dachis recently was named a top 10 finalist in the Lyfebulb/Novo Nordisk Innovation Award competition for the technology.

Insulia Eases Basal Insulin Dosing in Type 2 Diabetes

Indicated specifically for patients with type 2 diabetes who use basal insulin, Insulia (Voluntis) is a prescription-only platform that the physician sets up with a personalized treatment plan for the patient, allowing the device to provide dosing recommendations and educational coaching messages in response to blood glucose values and other diabetes-related data.

The dose-adjustment algorithm is embedded in the application and is accessible to the patient via a web portal or iOS and Android smartphones and tablets.

Patients' data are automatically shared with their healthcare providers, who can remotely monitor the patient's progress and send personalized notifications.

"This enables providers to deliver highly personalized telemedicine services, a practice increasingly supported by payers worldwide," according to a Voluntis company statement.

Dr Ahn commented, "Voluntis's system appears to address a key pain point in the current physician-patient interaction: Guided insulin dose titration. The current methodology it hopes to replace is complex and either errs toward oversimplified instructions or relies heavily on frequent communication."

But, he added, "A key challenge will be to convince doctors to actually change their practice behavior and give Voluntis a try."

Dr Ahn is the creator and co-owner of a glucose logbook diabetes app called Sugar Streak. He has no other relevant financial relationships.

For more diabetes and endocrinology news, follow us on Twitter and on Facebook.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: